GlassScriptPhysician profile
Robert H Lorenz
NPI 1245764307
$6,837.87
in general payments reported to CMS, 2019-2025
24 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $272 · 2022: $742 · 2023: $2,277 · 2024: $1,519 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,573 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,572.97 |
| Education | $250.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,515.57 | 2021-2025 | |
| Janssen Biotech, INC. | $1,395.41 | 2022-2025 | Tremfya |
| Pfizer INC. | $790.80 | 2021-2025 | |
| Incyte Corporation | $414.75 | 2021-2025 | Opzelura |
| Genzyme Corporation | $335.83 | 2022-2025 | |
| Ucb, INC. | $325.63 | 2023-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $296.54 | 2021-2025 | Ilumya |
| Galderma Laboratories, L.P. | $271.58 | 2021-2025 | Aklief, Oracea, Twyneo |
| Dermavant Sciences, INC. | $240.86 | 2023-2024 | Vtama |
| Leo Pharma INC. | $237.79 | 2023-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $192.81 | 2023-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $163.31 | 2023-2025 | Zoryve |
| Amgen INC. | $129.04 | 2021-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $116.23 | 2021-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $101.11 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $65.69 | 2022-2023 | Seysara |
| Lilly USA, LLC | $54.30 | 2023 | Taltz, Olumiant |
| Organon LLC | $44.75 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $42.81 | 2024-2025 | |
| Fidia Pharma USA INC. | $24.39 | 2024 | |
| Botanix Sb INC | $23.68 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $23.38 | 2023 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.43 | 2024 | Cabtreo, Jublia, Arazlo |
| Journey Medical Corporation | $13.18 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lorenz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.